Cargando…
Platelets, diabetes and myocardial ischemia/reperfusion injury
Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452354/ https://www.ncbi.nlm.nih.gov/pubmed/28569217 http://dx.doi.org/10.1186/s12933-017-0550-6 |
_version_ | 1783240397030424576 |
---|---|
author | Russo, Isabella Penna, Claudia Musso, Tiziana Popara, Jasmin Alloatti, Giuseppe Cavalot, Franco Pagliaro, Pasquale |
author_facet | Russo, Isabella Penna, Claudia Musso, Tiziana Popara, Jasmin Alloatti, Giuseppe Cavalot, Franco Pagliaro, Pasquale |
author_sort | Russo, Isabella |
collection | PubMed |
description | Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs. |
format | Online Article Text |
id | pubmed-5452354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54523542017-06-01 Platelets, diabetes and myocardial ischemia/reperfusion injury Russo, Isabella Penna, Claudia Musso, Tiziana Popara, Jasmin Alloatti, Giuseppe Cavalot, Franco Pagliaro, Pasquale Cardiovasc Diabetol Review Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs. BioMed Central 2017-05-31 /pmc/articles/PMC5452354/ /pubmed/28569217 http://dx.doi.org/10.1186/s12933-017-0550-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Russo, Isabella Penna, Claudia Musso, Tiziana Popara, Jasmin Alloatti, Giuseppe Cavalot, Franco Pagliaro, Pasquale Platelets, diabetes and myocardial ischemia/reperfusion injury |
title | Platelets, diabetes and myocardial ischemia/reperfusion injury |
title_full | Platelets, diabetes and myocardial ischemia/reperfusion injury |
title_fullStr | Platelets, diabetes and myocardial ischemia/reperfusion injury |
title_full_unstemmed | Platelets, diabetes and myocardial ischemia/reperfusion injury |
title_short | Platelets, diabetes and myocardial ischemia/reperfusion injury |
title_sort | platelets, diabetes and myocardial ischemia/reperfusion injury |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452354/ https://www.ncbi.nlm.nih.gov/pubmed/28569217 http://dx.doi.org/10.1186/s12933-017-0550-6 |
work_keys_str_mv | AT russoisabella plateletsdiabetesandmyocardialischemiareperfusioninjury AT pennaclaudia plateletsdiabetesandmyocardialischemiareperfusioninjury AT mussotiziana plateletsdiabetesandmyocardialischemiareperfusioninjury AT poparajasmin plateletsdiabetesandmyocardialischemiareperfusioninjury AT alloattigiuseppe plateletsdiabetesandmyocardialischemiareperfusioninjury AT cavalotfranco plateletsdiabetesandmyocardialischemiareperfusioninjury AT pagliaropasquale plateletsdiabetesandmyocardialischemiareperfusioninjury |